Literature DB >> 17251419

Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease.

Pascale N Lacor1, Maria C Buniel, Paul W Furlow, Antonio Sanz Clemente, Pauline T Velasco, Margaret Wood, Kirsten L Viola, William L Klein.   

Abstract

The basis for memory loss in early Alzheimer's disease (AD) seems likely to involve synaptic damage caused by soluble Abeta-derived oligomers (ADDLs). ADDLs have been shown to build up in the brain and CSF of AD patients and are known to interfere with mechanisms of synaptic plasticity, acting as gain-of-function ligands that attach to synapses. Because of the correlation between AD dementia and synaptic degeneration, we investigated here the ability of ADDLs to affect synapse composition, structure, and abundance. Using highly differentiated cultures of hippocampal neurons, a preferred model for studies of synapse cell biology, we found that ADDLs bound to neurons with specificity, attaching to presumed excitatory pyramidal neurons but not GABAergic neurons. Fractionation of ADDLs bound to forebrain synaptosomes showed association with postsynaptic density complexes containing NMDA receptors, consistent with observed attachment of ADDLs to dendritic spines. During binding to hippocampal neurons, ADDLs promoted a rapid decrease in membrane expression of memory-related receptors (NMDA and EphB2). Continued exposure resulted in abnormal spine morphology, with induction of long thin spines reminiscent of the morphology found in mental retardation, deafferentation, and prionoses. Ultimately, ADDLs caused a significant decrease in spine density. Synaptic deterioration, which was accompanied by decreased levels of the spine cytoskeletal protein drebrin, was blocked by the Alzheimer's therapeutic drug Namenda. The observed disruption of dendritic spines links ADDLs to a major facet of AD pathology, providing strong evidence that ADDLs in AD brain cause neuropil damage believed to underlie dementia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17251419      PMCID: PMC6672917          DOI: 10.1523/JNEUROSCI.3501-06.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  515 in total

Review 1.  Impaired regulation of synaptic actin cytoskeleton in Alzheimer's disease.

Authors:  Peter Penzes; Jon-Eric Vanleeuwen
Journal:  Brain Res Rev       Date:  2011-01-26

Review 2.  Synapses and Alzheimer's disease.

Authors:  Morgan Sheng; Bernardo L Sabatini; Thomas C Südhof
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-05-01       Impact factor: 10.005

Review 3.  Synaptic mitochondrial pathology in Alzheimer's disease.

Authors:  Heng Du; Lan Guo; Shirley ShiDu Yan
Journal:  Antioxid Redox Signal       Date:  2011-12-15       Impact factor: 8.401

Review 4.  New developments on the role of NMDA receptors in Alzheimer's disease.

Authors:  Roberto Malinow
Journal:  Curr Opin Neurobiol       Date:  2011-09-29       Impact factor: 6.627

5.  Donepezil in a narrow concentration range augments control and impaired by beta-amyloid peptide hippocampal LTP in NMDAR-independent manner.

Authors:  Nadezhda A Kapai; Julia V Bukanova; Elena I Solntseva; Vladimir G Skrebitsky
Journal:  Cell Mol Neurobiol       Date:  2011-10-04       Impact factor: 5.046

6.  A novel ARC gene polymorphism is associated with reduced risk of Alzheimer's disease.

Authors:  Sara Landgren; Malin von Otter; Mona Seibt Palmér; Caroline Zetterström; Staffan Nilsson; Ingmar Skoog; Deborah R Gustafson; Lennart Minthon; Anders Wallin; Niels Andreasen; Nenad Bogdanovic; Jan Marcusson; Kaj Blennow; Henrik Zetterberg; Petronella Kettunen
Journal:  J Neural Transm (Vienna)       Date:  2012-05-25       Impact factor: 3.575

7.  Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61.

Authors:  Pradeep Kurup; Yongfang Zhang; Jian Xu; Deepa V Venkitaramani; Vahram Haroutunian; Paul Greengard; Angus C Nairn; Paul J Lombroso
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

Review 8.  Role of Glutamate and NMDA Receptors in Alzheimer's Disease.

Authors:  Rui Wang; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

9.  Effects of edaravone on amyloid-β precursor protein processing in SY5Y-APP695 cells.

Authors:  Yue-E Shen; Yan Wang; Gui-Chun Yu; Chao Liu; Zhen-Yu Zhang; Li-Ming Zhang
Journal:  Neurotox Res       Date:  2013-01-17       Impact factor: 3.911

Review 10.  The neurodegeneration in Alzheimer disease and the prion protein.

Authors:  Gianluigi Forloni; Alessandra Sclip; Tiziana Borsello; Claudia Balducci
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.